Merck & Co., Ltd., Merck (China) Investment Co., Ltd., Propecia, an oral drug brand specializing in the treatment of male pattern baldness, is a world-famous multinational pharmaceutical company and a large pharmaceutical company in the United States
Propecia is the only finasteride drug approved by the US FDA for the treatment of male hair loss. The main ingredient of Propecia is finasteride, which is a synthetic steroidal compound, which is a specific inhibitor of the intracellular enzyme type II type 5a reductase in the process of androgen testosterone metabolism into dihydrotestosterone, through the inhibition of this enzyme, the concentration of dihydrotestosterone in the scalp and serum of patients decreases, thereby inhibiting the scalp hair follicles from becoming smaller and reversing the hair loss process. Propecia is an internal medication specifically used to treat androgenetic alopecia (male pattern daviness) and is effective in promoting hair growth and preventing continued hair loss.
Merck & CoIt is a world-renowned multinational pharmaceutical company, headquartered in New Jersey, USA (known as Merck & Co. in the United States), with more than 83,000 employees worldwide. Merck & Co., Ltd. is committed to medical research, development and sales of human and veterinary pharmaceutical products, its marketing network covers 70 countries and regions in the United States, Europe, Central and South America and Asia-Pacific, with 31 factories and 17 logistics distribution centers, and currently produces and sells more than 150 kinds of Merck products worldwide, with sales of 24.2 billion US dollars in 2007. Its revenue in 2012 was $47.3 billion, compared with R&D expenditures of $8.168 billion in the same year.
On March 9, 2009, Merck announced that it would acquire its rival Schering-Plough for $41.1 billion, and the two companies announced in a joint statement that the combined company would retain the Merck & Co. name. Richard T. Clark, President and Chief Executive Officer of Merck, will lead the new company. The merger will be paid in cash and stock, and Merck will become the second largest pharmaceutical company in the United States.
In 1992, Merck (China) Co., Ltd. was formally established. In 1994, Merck and Hangzhou Huadong Pharmaceutical Group Co., Ltd. established a joint venture, Hangzhou Merck Pharmaceutical Co., Ltd. Merck sells 17 products in China, most of which are already packaged or manufactured at the Hangzhou plant. The products cover a wide range of fields, and are in a leading position in many therapeutic fields such as lowering blood pressure, regulating blood lipids, treating prostatic hyperplasia, asthma, osteoarthritis, osteoporosis, male alopecia and AIDS. There are also a range of vaccines to prevent hepatitis A, measles, rubella, mumps, and diseases caused by pneumococcus and Haemophilus influenzae. With more than 4,500 employees in China and 14 offices across the country, Merck China will continue to expand its workforce and develop a grand plan to "win in China", hoping to achieve results in the Chinese market that matches its status as a global pharmaceutical giant.
